Study guide
18.2 Tumor Lysis Syndrome
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
18.2 Tumor Lysis Syndrome
Key Takeaways Explain This Topic AI
High-burden ALL, Burkitt lymphoma, other high-grade NHL, and sometimes AML drive tumor lysis syndrome: hyperkalemia, hyperphosphatemia, secondary hypocalcemia, hyperuricemia, and acute kidney injury.
Cairo-Bishop is a known laboratory-versus-clinical TLS framework; CPHON items test the pattern and the actions, not reciting every cutoff as if ONCC published it.
Prevention starts with hydration that has no potassium in the initial fluids, plus allopurinol to block new uric acid or rasburicase to destroy existing uric acid.
Rasburicase is contraindicated in G6PD deficiency; uric-acid samples after rasburicase must be placed on ice or the result is falsely low.
Treat hyperkalemia on telemetry with protocol kayexalate, insulin-glucose, cardioprotective calcium, and dialysis; treat tetany or arrhythmia from hypocalcemia, but be cautious replacing calcium while phosphate remains very high.
Last updated: August 2026
CPHON TCO V.C.3 is tumor lysis syndrome (TLS) : the metabolic crash when a large mass of cancer cells dies at once and dumps intracellular contents into blood. It is a preventable emergency if hydration and uric-acid control start before or with the first cytoreductive doses, and it is a dialysis emergency if potassium and the kidney get ahead of you.
Who is at risk
Highest pediatric risk is high-burden acute lymphoblastic leukemia (ALL) , Burkitt lymphoma , and other high-grade non-Hodgkin lymphomas (NHL) with bulky nodes or a large abdomen. Acute myeloid leukemia (AML) can cause TLS, especially with a high white-cell count, but Burkitt and T-ALL or B-ALL with a packed marrow or mediastinum are the classic CPHON pictures. Spontaneous TLS can start before chemotherapy when cells are already turning over. Induction steroids, hydroxyurea, the first chemotherapy block, and even the fall in uric acid after rasburicase as remaining cells lyse can accelerate the dump.
A 6-year-old with a rock-hard abdomen from Burkitt lymphoma, uric acid already high, lactate dehydrogenase (LDH) sky-high, and a white-cell count in the six figures is a TLS admission before the first vincristine or cyclophosphamide bag. A “well-looking” preschooler with newly diagnosed ALL and a potassium of 5.8 mEq/L on the diagnostic chemistry panel is not “fine to wait until Monday.” Risk climbs with high LDH, high baseline uric acid, bulky disease, preexisting dehydration or renal impairment, acidic urine, and oliguria. The nurse does not need a research-score calculator to start precautions; the diagnosis plus a high burden is enough to open the TLS order set.
The laboratory four and the kidney
Dying cells release potassium , phosphate , and purines that become uric acid . Phosphate binds calcium, so secondary hypocalcemia follows hyperphosphatemia . Uric acid precipitates in renal tubules; the calcium-phosphate product can do the same. The organ that fails is the kidney : oliguria, rising creatinine, and then a potassium that no longer has an exit.
Remember the direction , not a trivia museum:
Hyperkalemia — arrhythmia, peaked T waves, widened QRS, sine-wave risk.
Hyperphosphatemia
Hypocalcemia (secondary) — tetany, Chvostek or Trousseau signs in older children, seizures, prolonged QT, arrhythmia.
- Hyperuricemia
- Acute kidney injury (AKI)
Cairo-Bishop is a widely used laboratory versus clinical TLS framework in oncology (two or more laboratory shifts in a defined peri-therapy window for laboratory TLS; clinical TLS adds creatinine rise, arrhythmia, seizure, or death). You may name that framework. Do not treat every numeric cutoff as if ONCC published it. CPHON items test whether you recognize the pattern and act, not whether you can recite an adult paper’s milligram-per-deciliter table from memory.
Prevention: water first, then the uric-acid drug
Hydration is the intervention that actually protects tubules. Typical pediatric orders run two to four times maintenance (often about 2–3 L/m²/day on cooperative-group pathways) with no potassium in the initial fluids . Adding potassium to “make the bag complete” is how you help a lysing child fibrillate. Alkalinization of urine was used historically with allopurinol to keep uric acid soluble; many contemporary rasburicase-based pathways omit routine bicarbonate because alkaline urine can worsen calcium-phosphate precipitation. Follow the protocol in front of you; do not invent bicarbonate as a CPHON default.
Two uric-acid strategies, different jobs:
Allopurinol inhibits xanthine oxidase so the child makes less new uric acid . It does not destroy uric acid already in plasma. It is prevention and slower control.
Rasburicase is recombinant urate oxidase . It converts existing uric acid to allantoin , which is far more soluble, and the uric acid falls within hours. It is the drug for established hyperuricemia and for the highest-burden Burkitt and ALL pictures.
Rasburicase is contraindicated in glucose-6-phosphate dehydrogenase (G6PD) deficiency because the hydrogen peroxide generated can cause hemolysis and methemoglobinemia . Screen when time allows, especially in populations with higher G6PD prevalence, and never give rasburicase to a child with known G6PD deficiency. After rasburicase, uric acid samples must be placed on ice and assayed immediately ; the enzyme keeps working in a warm tube and produces a falsely low uric acid. Treating a “normal” room-temperature uric acid after rasburicase as proof that TLS has resolved is a lab-handling error.
Hyperkalemia, calcium, and dialysis
Put the child on telemetry once TLS is in play or potassium is rising. Stop potassium in fluids, diet, and additives. Protocol potassium treatments, used as ordered:
Sodium polystyrene sulfonate (kayexalate) binds potassium in the gut—slower, not a code drug.
Insulin plus glucose drives potassium intracellularly—faster temporizing.
Calcium (gluconate or chloride per setting) protects the myocardium when electrocardiogram (ECG) changes are present; it does not lower serum potassium.
Beta-agonists and loop diuretics appear on some pathways if the child still makes urine and can tolerate volume shifts.
Dialysis for refractory hyperkalemia, volume overload, uremia, or a calcium-phosphate crisis the kidney cannot clear.
Hypocalcemia: treat tetany, seizures, and arrhythmia . If phosphate is still extremely high and the child is asymptomatic, many teams hold aggressive calcium replacement to avoid precipitating more calcium-phosphate in tissues and kidneys. That caution is the CPHON trap. A child with a calcium of 6.2 mg/dL who is seizing still gets calcium; a quiet child with the same number and a phosphate of 12 mg/dL is a nephrology conversation, not a reflex calcium-gluconate race.
A 6-year-old Burkitt patient on hour 8 of induction who develops peaked T waves, oliguria, phosphate 11 mg/dL, calcium 6.4 mg/dL, and uric acid falling after rasburicase is still a TLS emergency: telemetry, insulin-glucose and cardioprotective calcium as ordered, hold extra calcium once tetany is absent if phosphate remains extreme, and call for dialysis rather than stacking oral binders at the bedside while the QRS widens. A 15-year-old with T-ALL and a mediastinal mass needs the same chemistry clock even if the airway crisis stole the first hour of attention.
Problem Why it happens Nursing move
Hyperkalemia Intracellular K released Telemetry; no K in fluids; insulin-glucose, kayexalate, calcium for ECG changes; dialysis
Hyperphosphatemia Intracellular phosphate released Hydration; phosphate binders as ordered; caution with calcium
- Hypocalcemia Secondary to high phosphate Treat tetany or arrhythmia; do not blindly normalize Ca
- Hyperuricemia Purine breakdown Allopurinol prevents new; rasburicase destroys existing; ice the tube
- AKI Crystal nephropathy, hypovolemia Hydration without K; urine output; dialysis if the kidney is closed
That is TCO V.C.3: name high-burden ALL, Burkitt, and NHL, watch the four labs plus the kidney, hydrate without potassium, choose allopurinol versus rasburicase with the G6PD and ice-tube rules, and treat potassium and symptomatic hypocalcemia as cardiac emergencies.